Pharmaceutical

Macau approves IASO Bio’s multiple myeloma therapy

The Macau Special Administrative Region (ISAF) Pharmaceutical Administration Bureau has approved IASO Bio's NDA for equecabtagene autoleucel.

Mar 29, 2025 - 06:00
Macau approves IASO Bio’s multiple myeloma therapy
The Macau Special Administrative Region (ISAF) Pharmaceutical Administration Bureau has approved IASO Bio's NDA for equecabtagene autoleucel.
Read the original article

Tags:

Previous Article

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Next Article

MSD’s subcutaneous Keytruda non-inferior to IV version of blockbuster drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Why Sanofi got shellacked

STAT+: Why Sanofi got shellacked

Oct 28, 2023

STAT+: DOJ, FTC primed for more aggressive scrutiny of health care mergers

STAT+: DOJ, FTC primed for more aggressive scrutiny of ...

Jul 20, 2023

MeiraGTx and Hologen launch AI-backed gene therapy venture

MeiraGTx and Hologen launch AI-backed gene therapy venture

Mar 15, 2025